Hepatitis C new medicine! Gilead Epclusa has a virological cure rate of 92-95% in patients aged 6-18

For hCV children under 12 years of age, especially those infected with HCV genotypes 2 and 3, the approved HCV treatment optionishes are limitedIn an open label study of pediatric patients aged 6-18 with HCV genotypes 1, 2, 3, 4, and 6, the Epclusa 12-week program had a viral cure rate of 95% (97/102) (97/102) in patients aged 12 to 18 years old (97/102) and a viral cure rate of 92% (67/73) in patients aged 6 to 12 yearsIn the study, the severity of most adverse events was mild or moderate, with four patients suffering from severe adverse events, one of which was attributed to treatmentThe most common adverse events (15% of patients): Headache, fatigue and nausea in adolescent patients, vomiting, coughing and headache in children aged 6-12 yearsCurrently, the study is treating children with hepatitis C between the ages of 3 and 6In the above-mentioned group of pediatric patients, the use of Epclusa is research-oriented and its safety and efficacy have not been determinedEpclusa is the world's first all-oral, generic, single tablet of hepatitis C treatment, once a day for the treatment of all 6 genotypes (GT-1, -2, -3, -4, -5, -6) hepatitis C patientsThe drug is made up of Gilead's listed hepatitis C star drug, sofosbuvir, and another antiviral drug, velpatasvirSofosbuvir is a nucleoside analogupolymer polymerase inhibitor, and velpatasvir is a generic NS5A inhibitorIn the United States, Epclusa is suitable for chronic HCV genotype 1-6 infection: (1) Epclusa monotherapy for 12 weeks in patients with hepatitis C without cirrhosis or with reimbursable period cirrhosis (Child-Pugh A grade); Epclusa combined ribavirin (RBV) for 12 weeks for hepatitis C patients with child-Pugh B or C stage of indemnification;Gilead: 4 generations of hepatitis C products, 3 generations approved for listing in China
Gilead has developed four generations of hepatitis C products, three of which have been approved in China: (1) September 25, 2017, Sovaldi (So) Vardy, generic name: Sophobuvir, sofosbuvir, 400mg tablets) approved in combination with other drugs used to treat fullgenotypes (1-6) hepatitis C virus infection in adults and 12-18 year olds, this time Approved to make Sovaldi the first officially approved hepatitis C treatment drug in China; (2) May 30, 2018, Epclusa (Clusha, generic name: Sophophosphate cloth) V/Vipatavir, sofosbuvir/velpatasvir, 400mg/100mg tablet) approved for the treatment of adult infections with genotype 1-6, hybrid and unknown chronic HCV, this approval, Epclusa (c) became China's first pan-gene HCV single tablet solution(3) On 4 December 2018, Harvoni (Shafanning, ledipasvir/sofosbuvir, LediPave 90mg/Sorponbuvir 400mg) was approved for the treatment of adults infected with chronic hepatitis C virus (HCV) type 1-6 and adolescents aged 12-18 yearsOf the above three hepatitis C drugs, Sovaldi is commonly known internationally as "Ji generation", Harvoni is commonly known internationally as "Ji II" and Epclusa is commonly known as "Ji III" in the international communityThe "Ji IV Generation" is Vosevi (SOF/VEL/VOX, Sofobuvir/Vipatavir/Vosirevir tablet), the first single tablet in the world to be approved as a rescue therapy for specific hepatitis C patients, and the receiving end of Gilead's SOF-based HCV Direct Effect Antiviral (DAA) drug pipelineVosevi consists of two components (SOF/VEL) and voxilaprevir in Epclusa, a generic hepatitis C cocktail therapy that is listed by Gilead, where sOF is a nucleoside analogue polymerase inhibitor, VEL is a generic NS5A inhibitor, and voxilaprevir is a generic NS3 protease inhibitorOn June 12 this year, Vosevi 's listing application in China was accepted under the registration number JXHS1900078, which has been included in the first list of clinically urgent lying new drugs issued by the National Bureau notably, four U.S drug labels have a black-box warning that the drug may be at risk of causing hepatitis B virus (HBV) to reactivate in patients with hepatitis C/HBV co-infection original origin: Gilead Announces New Data from Viral Research Programs at The Liver Meeting® 2019